Enliven Therapeutics (NASDAQ:ELVN) Stock Price Expected to Rise, HC Wainwright Analyst Says

Enliven Therapeutics (NASDAQ:ELVN) had its price target boosted by investment analysts at HC Wainwright from $65.00 to $73.00 in a research report issued to clients and investors on Monday, Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price objective suggests a potential upside of 76.97% from the stock’s current price. HC Wainwright also issued estimates for Enliven Therapeutics’ FY2027 earnings at ($2.06) EPS.

ELVN has been the topic of several other reports. The Goldman Sachs Group boosted their price objective on Enliven Therapeutics from $67.00 to $80.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Mizuho upped their price objective on Enliven Therapeutics from $62.00 to $73.00 and gave the company an “outperform” rating in a research report on Tuesday, August 18th. Stifel Nicolaus raised their price objective on Enliven Therapeutics from $80.00 to $82.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enliven Therapeutics in a research note on Thursday, October 15th. Finally, William Blair initiated coverage on Enliven Therapeutics in a report on Tuesday, August 18th. They issued an “outperform” rating for the company. Ten equities research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $75.44.

Enliven Therapeutics Price Performance

Shares of NASDAQ:ELVN opened at $41.25 on Monday. Enliven Therapeutics has a 52 week low of $14.78 and a 52 week high of $62.32. The firm has a fifty day simple moving average of $51.25 and a two-hundred day simple moving average of $47.98.

Enliven Therapeutics (NASDAQ:ELVN) last posted its earnings results on Wednesday, August 5th. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.10). On average, equities research analysts predict that Enliven Therapeutics will post -1.81 EPS for the current year.

Insider Activity

In related news, CFO Benjamin Hohl sold 6,018 shares of Enliven Therapeutics stock in a transaction dated Thursday, September 17th. The shares were sold at an average price of $50.35, for a total transaction of $303,006.30. Following the completion of the transaction, the chief financial officer directly owned 38,000 shares of the company’s stock, valued at approximately $1,913,300. The trade was a 13.67% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director J. Scott Garland sold 13,000 shares of the company’s stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $46.67, for a total transaction of $606,710.00. Following the transaction, the director owned 13,000 shares in the company, valued at $606,710. The trade was a 50.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 183,831 shares of company stock valued at $10,823,298. 3.00% of the stock is currently owned by company insiders.

Institutional Trading of Enliven Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP increased its stake in Enliven Therapeutics by 70.9% in the first quarter. Dimensional Fund Advisors LP now owns 681,715 shares of the company’s stock worth $26,714,000 after purchasing an additional 282,822 shares during the period. Legal & General Group Plc bought a new stake in shares of Enliven Therapeutics during the second quarter worth $1,671,000. Avidity Partners Management LP boosted its stake in shares of Enliven Therapeutics by 185.1% during the first quarter. Avidity Partners Management LP now owns 400,000 shares of the company’s stock valued at $15,680,000 after purchasing an additional 259,700 shares during the period. Nicholas Investment Partners LP purchased a new stake in shares of Enliven Therapeutics during the second quarter valued at $19,870,000. Finally, Stempoint Capital LP purchased a new stake in shares of Enliven Therapeutics during the first quarter valued at $14,247,000. 95.08% of the stock is owned by hedge funds and other institutional investors.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing targeted therapies for patients with cancer. The company uses small-molecule drug discovery and development to pursue treatments designed to address validated cancer targets and improve patient outcomes.

Enliven’s pipeline includes ELVN-001, an investigational BCR-ABL1 tyrosine kinase inhibitor being developed for the treatment of chronic myeloid leukemia, and ELVN-002, an investigational HER2 inhibitor intended for use in patients with HER2-positive solid tumors.